CLAIMS

1. Use of a Toll- Like Receptor (TLR) agonist for the manufacture of a medicament for the treatment of cancer in a mammal, wherein the cancer is present in a tissue that expresses TLR5, the TLR agonist comprising the amino acid sequence of SEQ ID NO: 8.

2. Use of a TLR agonist in the manufacture of a medicament for reducing cancer recurrence in a mammal, wherein the cancer is present in a tissue that expresses TLR5, the TLR agonist comprising the amino acid sequence of SEQ ID NO: 8.

3. The use of claim 2, wherein the cancer recurrence is selected from the group consisting of a metastasis and tumor regrowth.

4. The use of any one of the preceding claims, wherein the cancer does not express TLR.

5. The use of any one of the preceding claims, wherein the tissue is selected from the group consisting of liver, lung, bladder, and intestinal.

6. The use of any one of the preceding claims, wherein the cancer is selected from the group consisting of melanoma, colon, breast, prostate, and a hematological malignancy.

7. The use of any one of the preceding claims, wherein the cancer is a tumor.

8. The use of claim 6, wherein the hematological malignancy is lymphoma.

9. The use of any one of the preceding claims, wherein the agonist is used as a monotherapy.

10. The use of any one of the preceding claims, wherein the mammal is not receiving a combination cancer therapy.

11. The use of claim 10, wherein the mammal is not receiving chemotherapy or radiation therapy.

~~12. The use of any one of the preceding claims, wherein the mammal has sufficient innate immunity.~~

~~13~~12. The use of ~~claim 12~~any one of the preceding claims, wherein the ~~sufficient~~mammal has an innate immunity level which is equivalent to the level required for eligibility for a first or subsequent round of chemotherapy.

~~14~~13. The use of ~~claim 12~~any one of the preceding claims, wherein the mammal has a white blood cell count that is within the range of clinically normal.

~~15~~14. The use of any one of the preceding claims wherein the treatment further comprises a FAS agonist.

~~16~~15. The use of claim ~~15~~14, wherein the FAS agonist is a FAS agonist antibody.